PL3870288T3 - Przeciwciała przeciwko chemokinom pan-elr+ cxc do leczenia trądziku odwróconego - Google Patents
Przeciwciała przeciwko chemokinom pan-elr+ cxc do leczenia trądziku odwróconegoInfo
- Publication number
- PL3870288T3 PL3870288T3 PL19797521.2T PL19797521T PL3870288T3 PL 3870288 T3 PL3870288 T3 PL 3870288T3 PL 19797521 T PL19797521 T PL 19797521T PL 3870288 T3 PL3870288 T3 PL 3870288T3
- Authority
- PL
- Poland
- Prior art keywords
- elr
- pan
- treatment
- cxc chemokine
- hidradenitis suppurativa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748838P | 2018-10-22 | 2018-10-22 | |
| US201962791061P | 2019-01-11 | 2019-01-11 | |
| PCT/US2019/056250 WO2020086327A1 (en) | 2018-10-22 | 2019-10-15 | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3870288T3 true PL3870288T3 (pl) | 2025-03-17 |
Family
ID=68425364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19797521.2T PL3870288T3 (pl) | 2018-10-22 | 2019-10-15 | Przeciwciała przeciwko chemokinom pan-elr+ cxc do leczenia trądziku odwróconego |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US12037387B2 (pl) |
| EP (2) | EP3870288B1 (pl) |
| JP (2) | JP7171913B2 (pl) |
| KR (3) | KR20250029297A (pl) |
| CN (2) | CN118846041A (pl) |
| AU (1) | AU2019364239B2 (pl) |
| BR (2) | BR112021004900A2 (pl) |
| CA (1) | CA3117142A1 (pl) |
| DK (1) | DK3870288T3 (pl) |
| ES (1) | ES3009417T3 (pl) |
| FI (1) | FI3870288T3 (pl) |
| HR (1) | HRP20250145T1 (pl) |
| HU (1) | HUE070192T2 (pl) |
| IL (2) | IL282307B1 (pl) |
| LT (1) | LT3870288T (pl) |
| MA (1) | MA53976B1 (pl) |
| MD (1) | MD3870288T2 (pl) |
| MX (2) | MX2021004363A (pl) |
| MY (1) | MY197879A (pl) |
| NZ (1) | NZ775058A (pl) |
| PL (1) | PL3870288T3 (pl) |
| PT (1) | PT3870288T (pl) |
| RS (1) | RS66419B1 (pl) |
| SG (1) | SG11202102904TA (pl) |
| SI (1) | SI3870288T1 (pl) |
| TW (1) | TWI737000B (pl) |
| UA (1) | UA128649C2 (pl) |
| WO (1) | WO2020086327A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206457A (zh) * | 2020-04-24 | 2022-02-16 | 美商美國禮來大藥廠 | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2575884T (lt) * | 2010-06-03 | 2018-09-25 | Abbvie Biotechnology Ltd | Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui |
| JO3580B1 (ar) * | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
| US9290570B2 (en) * | 2013-03-15 | 2016-03-22 | Eli Lilly And Company | Pan-ELR+ CXC Chemokine Antibodies |
| KR101418306B1 (ko) * | 2013-03-19 | 2014-07-15 | 김대운 | 바지의 흘러내림 방지용 버팀기둥 |
| WO2015197098A1 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| CA2971168C (en) * | 2014-12-18 | 2019-08-20 | Csir | Immunomodulation by controlling elr+ proinflammatory chemokine levels with the long non-coding rna umlilo |
| CN110382001A (zh) * | 2017-02-16 | 2019-10-25 | 埃克斯生物科技公司 | 化脓性汗腺炎的治疗 |
-
2019
- 2019-10-08 TW TW108136327A patent/TWI737000B/zh active
- 2019-10-15 HR HRP20250145TT patent/HRP20250145T1/hr unknown
- 2019-10-15 CN CN202411069386.1A patent/CN118846041A/zh active Pending
- 2019-10-15 MA MA53976A patent/MA53976B1/fr unknown
- 2019-10-15 BR BR112021004900-2A patent/BR112021004900A2/pt unknown
- 2019-10-15 SI SI201930876T patent/SI3870288T1/sl unknown
- 2019-10-15 MX MX2021004363A patent/MX2021004363A/es unknown
- 2019-10-15 MY MYPI2021002149A patent/MY197879A/en unknown
- 2019-10-15 KR KR1020257005931A patent/KR20250029297A/ko active Pending
- 2019-10-15 MD MDE20210821T patent/MD3870288T2/ro unknown
- 2019-10-15 SG SG11202102904TA patent/SG11202102904TA/en unknown
- 2019-10-15 BR BR122023023399-9A patent/BR122023023399A2/pt unknown
- 2019-10-15 PL PL19797521.2T patent/PL3870288T3/pl unknown
- 2019-10-15 AU AU2019364239A patent/AU2019364239B2/en active Active
- 2019-10-15 CA CA3117142A patent/CA3117142A1/en active Pending
- 2019-10-15 ES ES19797521T patent/ES3009417T3/es active Active
- 2019-10-15 KR KR1020217011560A patent/KR102628314B1/ko active Active
- 2019-10-15 UA UAA202101781A patent/UA128649C2/uk unknown
- 2019-10-15 DK DK19797521.2T patent/DK3870288T3/da active
- 2019-10-15 EP EP19797521.2A patent/EP3870288B1/en active Active
- 2019-10-15 NZ NZ775058A patent/NZ775058A/en unknown
- 2019-10-15 US US17/284,611 patent/US12037387B2/en active Active
- 2019-10-15 EP EP24217370.6A patent/EP4545560A3/en active Pending
- 2019-10-15 HU HUE19797521A patent/HUE070192T2/hu unknown
- 2019-10-15 WO PCT/US2019/056250 patent/WO2020086327A1/en not_active Ceased
- 2019-10-15 RS RS20250038A patent/RS66419B1/sr unknown
- 2019-10-15 JP JP2021521030A patent/JP7171913B2/ja active Active
- 2019-10-15 KR KR1020247002081A patent/KR20240014601A/ko not_active Ceased
- 2019-10-15 LT LTEPPCT/US2019/056250T patent/LT3870288T/lt unknown
- 2019-10-15 PT PT197975212T patent/PT3870288T/pt unknown
- 2019-10-15 CN CN201980069911.0A patent/CN112912140B/zh active Active
- 2019-10-15 FI FIEP19797521.2T patent/FI3870288T3/fi active
-
2021
- 2021-04-13 IL IL282307A patent/IL282307B1/en unknown
- 2021-04-15 MX MX2025011694A patent/MX2025011694A/es unknown
-
2022
- 2022-11-02 JP JP2022176098A patent/JP7410256B2/ja active Active
-
2024
- 2024-06-05 US US18/734,020 patent/US20240425577A1/en active Pending
-
2025
- 2025-10-19 IL IL324054A patent/IL324054A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2599290B (en) | Minimizing transducer settling time | |
| IL276917A (en) | A process for the preparation of alubixivet | |
| IL275482A (en) | Asketamine for the treatment of depression | |
| IL268007A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis | |
| IL284338A (en) | Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa | |
| IL283948A (en) | Methods for treating depression | |
| PL3570940T3 (pl) | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x | |
| IL268569A (en) | Treatment of hidradenitis suppurativa | |
| IL324054A (en) | Pan-ELR+ CXC antibodies as a chemokine for the treatment of hidradenitis suppurativa | |
| PL3765440T3 (pl) | Sposób wytwarzania n-alkilonitratoetylonitroamin | |
| GB2587996B (en) | Structural body | |
| IL281254A (en) | A process for the preparation of lanbatinib | |
| EP4054602A4 (en) | EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS | |
| IL274363A (en) | Use of a specific siRNA against protein S for the treatment of hemophilia | |
| IL284307A (en) | Methods for treating hidradenitis suppurativa using LTA4H | |
| PL3599256T3 (pl) | Sposób wytwarzania poliorganosiloksanów | |
| PL3774752T3 (pl) | Sposób wytwarzania glicydolu | |
| HK40066571A (en) | Anti-il-alpha antibody for the treatment of hidradenitis suppurativa | |
| HUP1800278A2 (en) | Process for the preparation of boc-linagliptin | |
| HK40062407A (en) | Methods for the treatment of depression | |
| ZA201906058B (en) | Dynamic hand splint | |
| HK40044464A (en) | R-fadrozole for use in the treatment of aldostonerism | |
| HK40019205A (en) | Treatment of hidradenitis suppurativa | |
| HK40027562A (en) | Treating hidradenitis suppurativa with il-17 antagonists | |
| HK40018974A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |